MVASI vs ZEJULA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 13, 2026·How we rate

Possible drug interaction. MVASI and ZEJULA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	MVASI	ZEJULA
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-AWWB	NIRAPARIB TOSYLATE
Manufacturer	Amgen Inc	Glaxosmithkline
Dosage forms	Injectable	Tablet
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

mvasi zejula

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-AWWB

NIRAPARIB TOSYLATE

Manufacturer

Amgen Inc

Glaxosmithkline

Dosage forms

Injectable

Tablet

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Frequently asked questions

Which is better-rated, Mvasi or Zejula?

By our independent rating, Mvasi scores higher — 3.6 vs 3.5 out of 5 for Zejula. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Mvasi and Zejula?

Mvasi contains Bevacizumab-Awwb, while Zejula contains Niraparib Tosylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.